E986 CMAJ| AUGUST 20, 2018| VolUMe 190| ISSUe 33 patient's quality of life. The most
common adverse effects include vasomotor symptoms, such as hot flashes with nausea …

Background A phase II trial of combined androgen blockade (CAB) in patients with
advanced androgen receptor (AR)–positive salivary gland carcinoma (SGC) showed 40% of …

Background: SGCs are rare and heterogenous tumors (< 1% of all malignancies in Europe).
Among more than 20 histotypes, only salivary duct carcinoma (SDC) and adenocarcinoma …

e18091 Background: Salivary gland cancers (SGC) are rare malignancies with no standard
systemic therapy available for patients with recurrent or metastatic disease. Androgen …

METHODS This was a single-institution phase II trial. A two-stage Simon's design was
applied. The primary end point was confirmed objective response rate. Secondary end …

PURPOSE The activity of androgen-deprivation therapy (ADT) in androgen receptor–
positive (AR+) salivary gland carcinomas (SGCs) has been established in the past few …

Materials and Methods Retrospective cohort of all patients (pts) diagnosed with AR positive
SGC, who were treated with ADT in a Portuguese cancer centre, from January 2019 until …

Combined androgen blockade with leuprorelin acetate and bicalutamide could be equally
effective and less toxic than conventional chemotherapy for patients with androgen receptor …

In the article by Yoshino et al. in the Annals of Oncology, the authors report the results of a
subset of patients enrolled in the RECOURSE and J003 trials, concluding that patients with …

Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-
targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent …